The DOI matches its Crossref record.
Inhibition of the Accumulation of Uremic Toxins in the Blood and Their Precursors in the Feces after Oral Administration of Lebenin®, a Lactic Acid Bacteria Preparation, to Uremic Patients Undergoing Hemodialysis
Abstract
The plasma levels of phenol, p-cresol, and indican are markedly increased in uremic patients, and cannot be efficiently reduced by hemodialysis. Such uremic toxins, which are produced in the intestine as bacterial putrefactive metabolites, accumulate to a great degree in the feces of hemodialysis patients. Oral administration of Lebenin®, a preparation consisting of antibiotic-resistant lactic acid bacteria, reduced the levels of fecal putrefactive metabolites to levels comparable with those of healthy subjects. Moreover, the plasma level of indican also significantly decreased in these Lebenin-treated patients. An analysis of the fecal microflora revealed that a disturbed composition of the microflora characterized by an overgrowth of aerobic bacteria is restored to normal by oral administration of Lebenin in hemodialysis patients. These results thus demonstate that oral administration of lactic acid bacteria in uremic patients is effective in reducing the levels of uremic toxins, especially that of indican, in the blood by inhibiting bacterial production by means of correcting the intestinal microflora.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such beneficial effects of Lactobacillus could be the result of effects of this bacteria on the permeability and immune status of the gut epithelium.”
From The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease (2018) · cites this paper as [218]
Citations
Cited by
Sorted by citations
Items 201–297 of 297
New Tricks for Old Friends: Treating Gut Microbiota of Patients With CKD
Mafra, D., Kalantar‐Zadeh, K., & Moore, L. W. (2021) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2021.07.002 · Cited by 14
p-Cresol inhibits IL-12 production by murine macrophages stimulated with bacterial immunostimulant
Kawakami, K., Makino, I., Kato, I., et al. (2009) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923970802680299 · Cited by 14
“Furthermore, the fecal level of p-cresol is much higher than the blood level.((7)) Phenolic compounds, representative uremic toxins, cause deterioration of the clinical condition of CRF patients.”
BackgroundLesaffer, G., Smet, R. D., D'heuvaert, T., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00228.x · Cited by 14
Micronutrient Metabolism in Hemodialysis Patients
Guo, C.-H., Wang, C.-L., & Che, P.-C. (2011) · InTech eBooks · doi:10.5772/22788 · Cited by 12
“Himmelfarb J. (2008). Oxidative stress in hemodialysis.”
BackgroundEffects of the uremic toxin indoxyl sulphate on human microvascular endothelial cells
Colombo, G., Astori, E., Landoni, L., Garavaglia, M. L., Altomare, A., Lionetti, M. C., Gagliano, N., Giustarini, D., Rossi, R., Milzani, A., et al. (2022) · Journal of Applied Toxicology · doi:10.1002/jat.4366 · Cited by 11
“Regarding anaerobic bacteria, HD patients have a significantly lower number of Bifidobacteria and higher Clostridium perfringens (Hida et al., 1996).”
BackgroundUremic Toxins: Removal with Different Therapies
Vanholder, R. C., Glorieux, G., & Smet, R. V. D. (2003) · Hemodialysis International · doi:10.1046/j.1492-7535.2003.00033.x · Cited by 12
Live bacterial cells as orally delivered therapeutics
Prakash, S., & Bhathena, J. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.10.1281 · Cited by 12
Intestinal dysbiosis and probiotic use: its place in hepatic encephalopathy in cirrhosis
Dazıroğlu, M. E. Ç. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0776 · Cited by 11
“In people with endstage kidney disease, lactic acid bacteria have shown efficacy in altering the intestinal flora and thus reducing such toxins [72].”
BackgroundGut Microbiome and Kidney Disease in Pediatrics: Does Connection Exist?
Vasylyeva, T. L., & Singh, R. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00235 · Cited by 11
“The study of methanol breath content in ESRD on hemodialysis showed that methanol production could be substantially manipulated by the diet, which changed gut populations per se (Lee et al., 2012).”
BackgroundInfluentialAdvances in the Detection, Mechanism and Therapy of Chronic Kidney Disease
Dong, Y. J., Qu, X., Wu, G., Luo, X., Tang, B., Wu, F., Fan, L., Sooranna, D., & Liang, T. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191119094354 · Cited by 11
A New Method for Removal of Albumin‐Binding Uremic Toxins: Efficacy of an Albumin‐Dialysate
Abe, T., Abe, T., Abe, T., et al. (2001) · Therapeutic Apheresis and Dialysis · doi:10.1046/j.1526-0968.2001.005001058.x · Cited by 11
Self-citationHasani, M., Pilerud, Z. A., Kami, A., Vaezi, A. A., Sobhani, S., Ejtahed, H., & Qorbani, M. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998280396231212114345 · Cited by 10
Gut Microbiota and Renal Injury
Zhang, L., Zhang, W., & Nie, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2385-4_7 · Cited by 10
Gut flora may offer new therapeutic targets for the traditional Chinese medicine enteric dialysis
Shu, Z., Cao, Y., & Halmurat, U. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.614234 · Cited by 10
“A further contributing factor is a shift in the composition of the intestinal flora due to the uremic condition, favoring overgrowth of bacteria producing more toxic compounds (Figure 2) [33].”
BackgroundHyperoxia as a driver of gut dysbiosis
Wu, H., Zeng, W., Dai, N., Gu, J., He, Y., Qin, H., Lin, L., Fu, X., Fu, B., & Xing, Z. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1675652 · Cited by 11
Lee, J.-Y., Mahan, S. P., de Carvalho, T. P., Nguyen, H., Singai, C., Camacho, L., Tekeli, M., Kwon, Y., Lee, J., Santos, R. L., et al. (2026) · Science · doi:10.1126/science.ady5217 · Cited by 11
Khiabani, S. A., Haghighat, S., Khosroshahi, H. T., Asgharzadeh, M., & Kafil, H. S. (2023) · Health Promotion Perspectives · doi:10.34172/hpp.2023.29 · Cited by 9
Diet-mediated metaorganismal relay biotransformation: health effects and pathways
Li, Y., Cao, H., Wang, X., Guo, L., Ding, X., Zhao, W., & Zhang, F. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.2004993 · Cited by 9
Nataatmadja, M., Cho, Y., Campbell, K. L., & Johnson, D. W. (2018) · InTech eBooks · doi:10.5772/intechopen.69325 · Cited by 9
Mandal, A., Mandal, S., Roy, S., Patra, A., Pradhan, S., Das, K., Paul, T., Mondal, K. C., & Nandi, D. K. (2013) · e-SPEN Journal · doi:10.1016/j.clnme.2013.05.001 · Cited by 8
Intestinal dialysis for conservative management of Uremia
Puri, I., Shirazi, N. M., Yap, E., & Saggi, S. J. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000571 · Cited by 8
Optimizing chronic kidney disease management: The potential of a multi-strain probiotic formulation
Chafekar, D. S. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i1.101515 · Cited by 9
Lukichev, B. G., Rumyantsev, A. S., Panina, I. Y., & Акименко, В. Б. (2019) · Nephrology (Saint-Petersburg) · doi:10.24884/1561-6274-2018-23-1-18-31 · Cited by 9
“[88] Лебенин 25 больных на ГД Снижение индикана в фекалиях и сыворотке крови.”
Bifidobacteriaceae Family Diversity in Gut Microbiota of Patients with Renal Failure.
Hanifi, G. R., Kafil, H. S., Khosroshahi, H. T., Shapouri, R., & Asgharzadeh, M. (2021) · PubMed · doi:10.22092/ari.2020.352271.1557 · Cited by 8
Patra, A., Mandal, A., Roy, S., et al. (2014) · Biomedicine & Preventive Nutrition · doi:10.1016/j.bionut.2014.02.001 · Cited by 7
Meyer, T. W., & Hostetter, T. H. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10053-3 · Cited by 13
Trandafir, M.-F., Pîrcălăbioru, G. G., & Savu, O. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12500 · Cited by 6
“In ESRD, increased aerobic species, such as Enterococcus and Enterobacteriaceae , have been observed (11).”
BackgroundSaingam, P., Rasyid, R., Abrahamson, B., Lie, T. J., Godfrey, B. J., Himmelfarb, J., & Winkler, M. K. H. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1577556 · Cited by 6
GUT MICROBIOTA - KIDNEY AXIS. FEATURES IN DISEASES OF THE URINARY SYSTEM AND UROGENITAL TRACT
Прокопьева, Н. Э., Новикова, В. П., & Хавкин, А. И. (2023) · Медицина: теория и практика · doi:10.56871/mtp.2022.51.41.008 · Cited by 6
Inflammation in Chronic Kidney Disease
Raj, D. S., Pecoits‐Filho, R., & Kimmel, P. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00024-3 · Cited by 7
Mafra, D., Alvarenga, L., Cardozo, L., Schultz, J., Rosado, A. S., & Borges, N. A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10562-8 · Cited by 5
Mandal, A., Paul, T., Roy, S., Mandal, S., Pradhan, S., Das, K., Mondal, K. C., & Nandi, D. K. (2013) · Biologia · doi:10.2478/s11756-013-0278-z · Cited by 5
“Probiotics and prebiotics evaluate the impact on solute concentration in serum or on their faecal or urinary excretion (Hida et al. 1996).”
BackgroundThe gut microbiome and the kidney
Regunathan-Shenk, R., Shah, N. B., & Raj, D. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00031-8 · Cited by 5
Uddanam Kidney Nephropathy Under the Light of Metagenomics Perspective
Arun, P. V. P. S., Reddy, C. O., & Akhter, Y. (2018) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-018-0008-5 · Cited by 5
Abramowitz, M. K., Meyer, T. W., & Hostetter, T. H. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0987-2.00018-2 · Cited by 7
Vanholder, R. C., Smet, R. D., & Lameire, N. H. (2004) · Springer eBooks · doi:10.1007/978-1-4020-2275-3_2 · Cited by 5
The serum levels of P-cresol and Indoxyl sulfate in different hemodialysis vintage
Lin, C. (2011) · Journal of Clinical Medicine and Research · doi:10.5897/jcmr11.053 · Cited by 4
“Both of the toxins originated from the metabolism of amino acids by the intestinal flora and are strongly protein-bound (Niwa et al., 1981; Hida et al., 1996).”
BackgroundMoon, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020118 · Cited by 4
“In another interventional study, Lebenin, a preparation consisting of antibiotic-resistant lactic acid bacteria, efficiently reduced the levels of indoxyl sulfate and p-cresol in patients [100].”
BackgroundLecamwasam, A., Ekinci, E. I., Saffery, R., & Dwyer, K. M. (2020) · Biomedicines · doi:10.3390/biomedicines8090341 · Cited by 4
Böhler, H., Orth-Alampour, S., Baaten, C. C. F. M. J., et al. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb02386e · Cited by 4
Nagano, N., Futaya, M., Kohno, M., Nakano, O., Nishida, N., Matsuura, Y., Shimada, M., Ito, K., Ando, T., Tsutsui, T., et al. (2015) · Advances in Microbiology · doi:10.4236/aim.2015.57055 · Cited by 4
“Indeed, profound dysbiosis has been observed in both peritoneal dialysis (PD) and hemodialysis (HD) patients [5]-[7]; it is considered that uremic toxins and putrefactive substances that originate from this process may contribute to the deterioration of renal function, systemic inflammation, immunosuppression, cardiov…”
BackgroundInfluentialThe Role of Intestinal Bacterial Flora in the Tuning of the T Cell Repertoire
Sawamura, S., TANAKA, K. A., Noda, S., et al. (1999) · Immunobiology · doi:10.1016/s0171-2985(99)80051-5 · Cited by 4
Self-citationShafi, T., & Rhee, E. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00018-5 · Cited by 4
Dhungana, P., Dam, A., & Kiang, T. K. L. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01587-0 · Cited by 4
“They were fairly short in duration with a range from 1 month [181, 184] to 6 months [180, 186, 188].”
Kanasaki, A., KIMURA, T., Kitagawa, M., & Kishimoto, Y. (2023) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.69.268 · Cited by 3
Nwaga, I. O., Nzana, V. B., Bughe, R. N., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-03942-6 · Cited by 3
“Hence, it has been suggested that low-protein diets of pro-, pre-and synbiotics (oligofructose-enriched inulin, B. infantis , and L. acidophilus ), which promote symbiont growth, could reduce inflammation in CKD patients and slow its progression [13, 14, 16, 17].”
Aytbaev, K. A. A., Murkamilov, I. T., & Kaliev, R. R. K. (2016) · Russian Medicine · doi:10.18821/0869-2106-2016-22-4-157-162 · Cited by 3
Pletinck, A., Vanholder, R. C., & Glorieux, G. (2012) · doi:10.1002/9781118424032.ch5 · Cited by 3
Gut Microbiota as a Source of Uremic Toxins
Popkov, V. A., Zharikova, A. A., Demchenko, E. A., Andrianova, N. V., Zorov, D. B., & Plotnikov, E. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010483 · Cited by 29
“Moreover, it was found that the total presence of Klebsiella and Escherichia coli was significantly increased in the intestine of uremic patients [38].”
BackgroundResultInfluentialMalaweera, A., Huang, L., & McMahon, L. P. (2025) · Toxins · doi:10.3390/toxins17110548 · Cited by 2
“Alteration of the gut microbiome by overgrowth of harmful bacteria in kidney disease can lead to both the increased production and intestinal modification of PBTs [23].”
Roth-Stefanski, C. T., Dolenga, C. J. R., Nakao, L. S., Pecoits‐Filho, R., de Moraes, T. P., & Moreno-Amaral, A. N. (2019) · Current Nutrition & Food Science · doi:10.2174/1573401315666190215111402 · Cited by 2
de Araújo, É. M. R., Meneses, G. C., Carioca, A. A. F., Martins, A. M. C., Daher, E. D. F., & da Silva, G. B. (2022) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2022-0021pt · Cited by 3
Novel Combination Therapy to Target Heart and Kidney
Lekawanvijit, S., & Krum, H. (2014) · Springer eBooks · doi:10.1007/978-3-319-09162-4_19 · Cited by 2
Synthesis Of Bireciprocal Wave Digital Filters With Equiripple Amplitude And Phase
Yaseen, M. (2004) · doi:10.5281/zenodo.38156 · Cited by 2
Artificial cells for oral delivery of live bacterial cells for therapy
Prakash, S., Bhathena, J., & Urbanska, A. M. (2007) · Elsevier eBooks · doi:10.1533/9781845693077.3.189 · Cited by 2
Duranti, E. (2017) · Archives of Renal Diseases and Management · doi:10.17352/2455-5495.000017 · Cited by 2
“The administration of antibiotics reduces its urinary excretion, as a result of bacterial clearance that produces them [15, 16].”
BackgroundKantah, M., Catanzaro, R., Kumar, M., Ws, J., Marcellino, M. G., Chawapatrah, P., Srivastava, A., Marotta, C., Lorenzetti, A., Lorenzetti, A., et al. (2018) · Journal of Gastrointestinal & Digestive System · doi:10.4172/2161-069x.1000560 · Cited by 3
“There is an ever increasing data on the importance of microbiota modulation of stress response [53-56] and albeit limited report on the beneficial gut ecology interventions [57-59].”
BackgroundFeng, Y., Li, L., Guo, F., et al. (2018) · RSC Advances · doi:10.1039/c8ra08049f · Cited by 2
The gut microbiome in chronic kidney disease
Merino-Ribas, A., Costa, C. F. F. A., Azevedo, M. J., Alencastre, I. S., Pestana, M., Araújo, R., & Sampaio‐Maia, B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91313-3.00012-x · Cited by 2
Ross, S. J. (2011) · doi:10.1002/9781118785546.ch41 · Cited by 2
Abe, T. (1996) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.29.1529 · Cited by 2
Szczuko, M., Grudniewska, A., Durma, A. C., Małecki, R., Filipczyńska, I., Franek, E., & Kędzierska-Kapuza, K. (2025) · Nutrients · doi:10.3390/nu17132112 · Cited by 1
“The consumption of Bifidobacterium restores the proper balance of bacteria in the gastrointestinal tract by limiting the proliferation of aerobic bacteria [48,49].”
Patra, A., Mandal, A., Samanta, A., et al. (2014) · Cited by 1
Hida, M., Aiba, Y., Suzuki, N., et al. (1996) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.29.285 · Cited by 1
Self-citationImpact de la nutrition sur le microbiote intestinal dans la maladie rénale chronique
Koppe, L., & Soulage, C. O. (2022) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2022.07.005 · Cited by 2
Are Probiotics Needed in Nephrology?
Kuznetzova, A. B., Prazdnova, E. V., Chistyakov, V. A., Kutsevalova, O. Y., & Батюшин, М. М. (2022) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2022-26-4-18-30 · Cited by 1
Anandh, U., & Saxena, A. (2023) · Journal of Renal Nutrition and Metabolism · doi:10.4103/jrnm.jrnm_6_23 · Cited by 1
Compositional characteristics of the gut microbiome in patients with uremia
Wu, Z., Bian, M., Zhang, H., Wang, M., Wang, P., Shao, Y., Shen, L., & Zhu, G. (2024) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_554_23 · Cited by 1
10.1016/b978-1-4160-3105-5.50049-9
(2000) · Time to knit · doi:10.1016/b978-1-4160-3105-5.50049-9 · Cited by 1
Ackley, W., Soiefer, L., Etinger, A., & Lowenstein, J. (2018) · InTech eBooks · doi:10.5772/intechopen.70461 · Cited by 2
Bioecological control of organ failure: The role of enteral nutrition, probiotics and synbiotics
Bengmark, S. (2005) · Journal of Organ Dysfunction · doi:10.1080/17471060500223555 · Cited by 1
“There are good reasons also to expect beneficial effects of synbiotic treatment in chronic conditions such as inflammatory bowel disease (48), cancer, chronic kidney disease (49, 50) and chronic lung disease, but systematic studies are so far to a large extent lacking.”
BackgroundPre-, Pro-, and Synbiotics in Clinical Enteral Nutrition
Bengmark, S. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0379-7.50026-7 · Cited by 1
Bengmark, S., & Cresci, G. (2005)
Probiotics: Synergy with Drugs and Carcinogens in Diet
Salminen, S., El-Nezami, H. S., Salminen, E. K., et al. (2005) · CRC Press eBooks · doi:10.1201/9781420038255-11
Das Mikrobiom des Darms: Dysbiose
van der Giet, M. (2017) · Dialyse aktuell · doi:10.1055/s-0043-122669
“in einer japanischen Arbeitsgruppe vor über 20 Jahren bereits gezeigt werden, dass Dialysepatienten eine signifikant niedrigere Anzahl an Bifidobakterien-Spezies und einen höheren Anteil an Clostridium perfringens aufwiesen [10].”
BackgroundGut Microbiota as Signatures in Non-communicable Diseases and Mucosal Immunity
Behera, S. K., Praharaj, A. B., Chalikonda, G., Srivani, G., & Mahapatra, N. (2020) · Diagnostics and therapeutic advances in GI malignancies · doi:10.1007/978-981-15-2017-4_11
Review: Uremic Toxins and Gut Microbiome
Suzuki, T., & Abe, T. (2020) · Springer eBooks · doi:10.1007/978-981-15-7793-2_2
D-serine as a Novel Uremic Toxin
Ouchi, H., Hirakawa, Y., & Inagi, R. (2020) · Springer eBooks · doi:10.1007/978-981-15-7793-2_8
The Gut as a Source of Inflammation in Chronic Kidney Disease
Kamyar, L., & Nosratola, K.-Z. (2015)
Effect of Uremic Toxins on Nutritional Status
Bhalla, A. K. (2021) · Journal of Renal Nutrition and Metabolism · doi:10.4103/jrnm.jrnm_17_21
El-Nezami, H. S., Mykkänen, H. M., Salminen, S., et al. (2005) · CRC Press eBooks · doi:10.1201/9781420038255.ch11
Fiber (Prebiotics) and Probiotics
Bengmark, S. (2005) · CRC Press eBooks · doi:10.1201/9781420039191.ch10
Microbiome Derived Metabolites in CKD and ESRD
Paul, R., Feibig, C., & Raj, D. S. (2022) · Springer eBooks · doi:10.1007/978-3-031-11942-2_4
Kronik Böbrek Hastalıklarında Prebiyotik Kullanımının Hastalık Progresyonu Üzerine Etkileri
Yalçın, B., & Özkaya, Ş. Ö. (2024) · İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi · doi:10.38079/igusabder.1351434
Anandh, U., & Saxena, A. (2024) · Journal of Renal Nutrition and Metabolism · doi:10.4103/jrnm.jrnm_1_23 · Cited by 1
Phenol as a breath marker for hemodialysis of chronic kidney disease patients
Eickel, I., Zygmunt, A.-C., Streit, F., et al. (2025) · Journal of Breath Research · doi:10.1088/1752-7163/add958
“An accumulation of these substances is associated with several pathologies in context of renal failure.”
Zhang, X., Sun, J., Liu, J., et al. (2025) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaf083
王, 玉. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123374
消化管におけるプロバイオティクス・プレバイオティクスの機能 : 注目点と問題点
森下, 芳. (2000) · 腸内細菌学雑誌 = Journal of intestinal microbiology · doi:10.11209/jim1997.13.53
The Role of Gut Microbiota in Cardiovascular-Kidney-Metabolic Syndrome
Mihai, C., Dranga, M., Nedelciuc, O., & Prelipcean, C. C. (2025) · Springer eBooks · doi:10.1007/978-3-032-11445-7_7
Emerging Cardiovascular Risk Factors in Chronic Kidney Disease in the “Omics” Era: Gut and Beyond
Sumida, K., & Kovesdy, C. P. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.12.001
Liver flukes and kidney injury: systematic review of human and animal data (from 1950 to 2025)
Kovner, A. V., Kapushchak, Y. K., & Pakharukova, M. Y. (2026) · Journal of Helminthology · doi:10.1017/s0022149x26101187
“…had shown that the number of Acinetobacter cells increases in experimental uremia (Wang et al. 2012), and the overall number of aerobic bacterial cells (including Pseudomonas and Streptococcus ) increases in individuals with chronic kidney diseases (Hida et al. 1996; Ramezani and Raj 2014).”
Shen, Z., Gao, L., Wang, Y., Li, S., & Lu, L. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1884822
Metadata
- Authors
- Hida, M., Aiba, Y., Sawamura, S., Suzuki, N., Satoh, T., & Koga, Y.
- Affiliations
- Tokai University (JP)
- Wakamoto Pharmaceutical (Japan) (JP)
- Kidney Centre (PK)
- ORCID
- Koga, Yasuhiro
- Venue
- Nephron
- Publisher
- S. Karger AG
- Published
- 2008-12-24
- Volume
- 74
- Issue
- 2
- Pages
- 349-355
- ISSN
- 1660-8151 (ISSN-L)
- 2235-3186
- OpenAlex
- W2075674899
- Cited by
- 295
- References
- 0
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 9 · 2023: 15 · 2022: 19 · 2021: 14 · 2020: 20 · 2019: 21 · 2018: 24 · 2017: 18 · 2016: 16 · 2015: 21 · 2014: 12 · 2013: 15 · 2012: 5
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Nephron journals/Nephron journals (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- lactic acid bacteria, uremic toxins, hemodialysis, indican, p-cresol, phenols, gut microbiota, oral administration, uremic patients
- MeSH terms
- Administration, Oral, Adult, Bacteria, Aerobic, Bacteria, Anaerobic, Bifidobacterium, Capsules, Cresols, Feces, Female, Renal Dialysis, Humans, Indican, Lactobacillus acidophilus, Male, Middle Aged, Phenols, Enterococcus faecalis, Uremia, Phenol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
